Immunization of rabbits with a modified vaccinia Ankara recombinant virus bearing the HIV envelope antigen on its outer membrane

Virus Research

Volumn 90, Issue 1-2, 2002, Pages 243-251

  Barchichat, Sabrina ^a   Katz, Ehud ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

HIV; MVA; Recombinant

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE; CELL GROWTH; CELL TYPE; CHICKEN; CHIMERA; CONTROLLED STUDY; EMBRYO; FIBROBLAST; GENETIC TRANSFECTION; IMMUNIZATION; MAMMAL CELL; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN DOMAIN; RABBIT; VACCINIA VIRUS; VIROGENESIS; VIRUS RECOMBINANT; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; FIBROBLASTS; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNIZATION; MEMBRANE GLYCOPROTEINS; PLAQUE ASSAY; RABBITS; RECOMBINANT PROTEINS; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

CERCOPITHECUS AETHIOPS; GALLUS GALLUS; MAMMALIA; ORYCTOLAGUS CUNICULUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 0036891205     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(02)00200-9     Document Type: Article

References (16)

1. Carroll M.W., Moss B. Host range and cytopathologenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 238:1997;198-211.
2. Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:1985;3403-3409.
3. Graham R.C. Jr, Karnovsky M.J. Glomerular permeability. Ultrastructural cytochemical studies using peroxidases as protein tracers. J. Exp. Med. 124:1966;1123-1134.
4. Hirsch V.M., Fuerst T.R., Sutter G., Carroll M.W., Yang L.C., Goldstein S., Piatak M., Elkins W.R., Alvord W.G., Montefiori D.C., Moss B., Lifson J.D. Patterns of viral replication correlate with outcome in simian immunodefficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:1996;3741-3752.
5. Hochstein-Mintzel V., Hanichen T., Huber H.C., Stickl H. An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola. Zentralbl. Bakteriol. 230:1975;283-297.
6. Katz E., Moss B. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions. AID Res. Hum. Retroviruses. 13:1997;1497-1500.
7. Katz E., Wolffe E.J., Moss B. The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodefficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. J. Virol. 71:1997;3178-3187.
8. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London). 227:1970;680-685.
9. Mayr A., Stickl H., Muller H.K., Danner K., Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. 167:1978;375-390.
10. Mayr H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1991;1031-1038.
11. Ramirez J.C., Gherardi M.M., Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74:2000;923-933.
12. Schneider J., Gilbert S.G., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., Becker M., Sinden R., Smith G.L., Hill A.V.S. Enhanced immunogenicity for CD8+T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:1998;397-402.
13. Stittelaar K.J., Kulken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G.M., van Schalkwijk P., van der Kwast T., Wyatt L.S., Moss B., Osterhaus D.M.E. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 19:2001;3700-3709.
14. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA. 89:1992;10847-10851.
15. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 12:1994;1032-1240.
16. Turner G.S. Respiratory infection of mice with vaccinia virus. J. Gen. Virol. 1:1967;399-402.